` 8YY (Biolidics Ltd) vs FTSE Straits Times Singapore Comparison - Alpha Spread

8YY
vs
F
FTSE Straits Times Singapore

Over the past 12 months, 8YY has significantly outperformed FTSE Straits Times Singapore, delivering a return of +37% compared to the FTSE Straits Times Singapore's 0% growth.

Stocks Performance
8YY vs FTSE Straits Times Singapore

Loading
8YY
FTSE Straits Times Singapore
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
8YY vs FTSE Straits Times Singapore

Loading
8YY
FTSE Straits Times Singapore
Difference
www.alphaspread.com

Performance By Year
8YY vs FTSE Straits Times Singapore

Loading
8YY
FTSE Straits Times Singapore
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Biolidics Ltd vs Peers

FTSE Straits Times Singapore
8YY
ABT
ISRG
BSX
SYK
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Biolidics Ltd
Glance View

Market Cap
64.1m SGD
Industry
Health Care

Biolidics Ltd. operates as a medical technology company. The firm is primarily engaged in the research, experimental development, marketing, and distribution of biotechnology, life and medical science and electronics-related industrial design services and investment holdings. The company segments include cancer, infectious diseases and laboratory services. The cancer segment involves the identifying and assessing collaboration partners, technology, products and services, product development, and the management of global distributorship networks and direct customers in the cancer field. The infectious diseases segment involves the identifying and assessing collaboration partners, technology, products and services, product development, and the management of global distributorship networks and direct customers in the infectious diseases field. The laboratory services segment involves the business, operation and provision of laboratory services to customers.

8YY Intrinsic Value
0.001 SGD
Overvaluation 97%
Intrinsic Value
Price
Back to Top